Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
AssigneeTempus Labs, Inc.
InventorsAlan Chang, Denise Lau, Aly Azeem Khan
Life of this patent
Estimating the term…
Loading patent…
AssigneeTempus Labs, Inc.
InventorsAlan Chang, Denise Lau, Aly Azeem Khan
Estimating the term…
Provided herein are computer-implemented methods of identifying programmed-death ligand 1 (PD-L1) expression status of a subject's sample comprising a cancer cell. In exemplary embodiments, the method comprises receiving an unlabeled expression data set for the subject's sample; aligning the unlabeled expression data set to labeled expression data according to a trained PD-L1 predictive model, wherein the trained PD-L1 predictive model has been trained with a plurality of labeled expression data sets, each labeled expression data set comprising expression data for a sample of a labeled cancer type and a labeled PD-L1 expression status; wherein aligning the unlabeled gene expression data set to labeled expression data according to the trained PD-L1 predictive model identifies PD-L1 expression status for the subject's sample. Further provided are related methods of preparing a clinical decision support information (CDSI) report and methods of determining treatment for a subject. Additionally provided are CDSI reports and computing devices.
A computer-implemented method of identifying programmed-death ligand 1 (PD-L1) expression status of a subject's sample comprising a cancer cell, the method comprising:
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.